Financing Transformative Therapies: Cross-sector perspective on value, payment and real-world evidence

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Value based contracting approaches, which need to be informed by real-world evidence, become particularly worthwhile for high cost and curative therapies of which the volume-for-rebate paradigm is insufficient. A number of solutions have been discussed, including a third party serving as a “guarantor” of the effectiveness of a drug. Such an approach requires a tool to algorithmically predict and assess drug value as well as to translate this assessment into a “drug value marketplace.”

This panel discussion brings together perspectives from pharma, payers and investors to discuss requirements and challenges for such an approach, and considers alternative methods.
Moderator
photo
Vice President, Growth
Aetion
Speakers
photo
SVP, Head of Access Value & Evidence Strategy
bluebird bio
photo
CEO
Health Capital Group
photo
VP Patient Health & Impact, Vaccines
Pfizer
photo
EVP & Chief Clinical Officer
Cigna Corporation
photo
Vice President, Growth
Aetion